|
US8685980B2
(en)
*
|
2008-08-22 |
2014-04-01 |
Novartis Ag |
Pyrrolopyrimidine compounds and their uses
|
|
WO2010132725A2
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US20130035336A1
(en)
*
|
2010-04-13 |
2013-02-07 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
|
|
CN106198656B
(zh)
|
2010-08-18 |
2018-12-11 |
生命科技股份有限公司 |
用于电化学检测装置的微孔的化学涂层
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
EP2632467B1
(en)
*
|
2010-10-25 |
2016-06-22 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
AR083797A1
(es)
*
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
CN103501789A
(zh)
|
2010-11-17 |
2014-01-08 |
北卡罗来纳大学查珀尔希尔分校 |
通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
|
|
CN103402996B
(zh)
*
|
2011-01-04 |
2015-02-11 |
诺瓦提斯公司 |
可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
|
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
|
BR112013033940A2
(pt)
*
|
2011-07-01 |
2017-02-14 |
Novartis Ag |
terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
|
|
ES2610931T3
(es)
*
|
2011-07-01 |
2017-05-04 |
Novartis Ag |
Terapia de combinación
|
|
WO2013059634A1
(en)
|
2011-10-20 |
2013-04-25 |
The Regents Of The University Of California |
Use of cdk9 inhibitors to reduce cartilage degradation
|
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
CN104302620A
(zh)
*
|
2012-04-26 |
2015-01-21 |
弗朗西斯·泽维尔·塔瓦雷斯 |
内酰胺的合成
|
|
CN105121429B
(zh)
|
2012-06-28 |
2017-12-12 |
诺华股份有限公司 |
补体途径调节剂和其用途
|
|
ES2648962T3
(es)
|
2012-06-28 |
2018-01-09 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la vía del complemento
|
|
EP2867225B1
(en)
|
2012-06-28 |
2017-08-09 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
ES2644700T3
(es)
|
2012-06-28 |
2017-11-30 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
|
EP2867227B1
(en)
|
2012-06-28 |
2018-11-21 |
Novartis AG |
Complement pathway modulators and uses thereof
|
|
BR112015000578A2
(pt)
|
2012-07-12 |
2017-06-27 |
Novartis Ag |
moduladores da via do complemento e usos dos mesmos
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
EP2880448B1
(en)
|
2012-08-03 |
2022-06-29 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
|
EP3251673A1
(en)
|
2012-12-13 |
2017-12-06 |
IP Gesellschaft für Management mbH |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
|
EP2934515B1
(en)
|
2012-12-20 |
2018-04-04 |
Novartis AG |
A pharmaceutical combination comprising binimetinib
|
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
EP3327144B1
(en)
|
2013-02-25 |
2020-03-25 |
Novartis AG |
Novel androgen receptor mutation
|
|
JP2016512559A
(ja)
|
2013-03-13 |
2016-04-28 |
アッヴィ・インコーポレイテッド |
Ｃｄｋ９キナーゼ阻害薬
|
|
JP2016516710A
(ja)
|
2013-03-13 |
2016-06-09 |
アッヴィ・インコーポレイテッド |
ピリジン系ｃｄｋ９キナーゼ阻害薬
|
|
EP2970299A1
(en)
*
|
2013-03-14 |
2016-01-20 |
Abbvie Inc. |
Pyrrolopyrimindine cdk9 kinase inhibitors
|
|
TW201446763A
(zh)
|
2013-03-14 |
2014-12-16 |
Abbvie Inc |
吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
|
|
CA2905935A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
|
|
CN105407723A
(zh)
*
|
2013-03-15 |
2016-03-16 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
WO2014144847A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
US20140274896A1
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
PL2976106T3
(pl)
|
2013-03-21 |
2021-10-25 |
Array Biopharma Inc. |
Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor
|
|
AU2014253932B2
(en)
|
2013-04-16 |
2020-04-30 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for CDK4 inhibitors
|
|
MX384403B
(es)
|
2013-08-14 |
2025-03-14 |
Novartis Ag |
Terapia de combinación para el tratamiento del cáncer.
|
|
AU2014312261A1
(en)
*
|
2013-08-28 |
2016-03-10 |
Novartis Ag |
Combination of an ALK inhibitor and a CDK inhibitor for the treatment of cell proliferative diseases
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
AR097894A1
(es)
*
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
US20160257688A1
(en)
*
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
CA2929620A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Novartis Ag |
Combination therapy comprising an inhibitor of jak, cdk and pim
|
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
|
EP3082423B1
(en)
*
|
2013-12-20 |
2024-12-11 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
MX2016008362A
(es)
*
|
2013-12-23 |
2016-09-08 |
Novartis Ag |
Combinaciones farmaceuticas.
|
|
CN105848656B
(zh)
*
|
2013-12-23 |
2019-10-25 |
诺华股份有限公司 |
药物组合
|
|
PL3091008T3
(pl)
*
|
2013-12-31 |
2018-12-31 |
Xuanzhu Pharma Co., Ltd. |
Inhibitor kinazy i jego zastosowanie
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
JP6783224B2
(ja)
|
2014-04-04 |
2020-11-11 |
デル マー ファーマシューティカルズ |
肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
|
|
WO2015160986A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
BR112016027679B1
(pt)
*
|
2014-05-28 |
2022-10-25 |
Chongqing Fochon Pharmaceutical Co., Ltd |
Inibidores de proteína quinase, seu usos e seus métodos de fabricação, kit e composição farmacêutica
|
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US10300073B2
(en)
|
2014-10-14 |
2019-05-28 |
The Regents Of The University Of California |
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
HUE061672T2
(hu)
|
2014-11-12 |
2023-08-28 |
Seagen Inc |
Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
|
|
EP3231805B1
(en)
*
|
2014-12-12 |
2020-03-04 |
Crystal Pharmatech Co. Ltd. |
Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
|
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
|
US20160220569A1
(en)
*
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|
|
CA2979215A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
JP2018509448A
(ja)
|
2015-03-25 |
2018-04-05 |
ノバルティス アーゲー |
組合せ医薬
|
|
ES2938261T3
(es)
|
2015-04-16 |
2023-04-05 |
Novartis Ag |
Comprimido de ribociclib
|
|
CN106146515B
(zh)
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
TWI696617B
(zh)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
AR104789A1
(es)
|
2015-05-29 |
2017-08-16 |
Teijin Pharma Ltd |
Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
|
|
CN105037236B
(zh)
*
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
|
JP2018526376A
(ja)
*
|
2015-08-28 |
2018-09-13 |
ノバルティス アーゲー |
がんの治療または予防のための（ａ）サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｌｅｅ０１１（＝リボシクリブ）および（ｂ）上皮成長因子受容体（ｅｇｆｒ）阻害剤のエルロチニブを含む医薬組み合わせ物
|
|
WO2017037575A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
EP3340987A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
EP3340991A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
|
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
|
KR102833068B1
(ko)
|
2015-12-17 |
2025-07-14 |
노파르티스 아게 |
Pd-1에 대한 항체 분자 및 그의 용도
|
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10570141B2
(en)
|
2016-03-25 |
2020-02-25 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
|
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
|
EP3445765A4
(en)
*
|
2016-04-22 |
2019-09-18 |
Dana Farber Cancer Institute, Inc. |
DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
RU2738837C2
(ru)
|
2016-05-07 |
2020-12-17 |
Шанхай Фокон Фармасьютикал Ко., Лтд. |
Некоторые ингибиторы протеинкиназы
|
|
WO2017211245A1
(zh)
*
|
2016-06-06 |
2017-12-14 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
|
EA202092441A1
(ru)
|
2016-06-07 |
2021-05-21 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
CN109789143A
(zh)
*
|
2016-07-01 |
2019-05-21 |
G1治疗公司 |
基于嘧啶的抗增殖剂
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
MX383803B
(es)
|
2016-07-01 |
2025-03-14 |
G1 Therapeutics Inc |
Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas.
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
MX2019002115A
(es)
|
2016-08-23 |
2019-07-08 |
Eisai R&D Man Co Ltd |
Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
|
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CA3040815C
(en)
|
2016-10-20 |
2021-07-20 |
Steven Martin Evans |
Anti-proliferative agents for treating pah
|
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
|
EP3538148A1
(en)
|
2016-11-08 |
2019-09-18 |
Dana-Farber Cancer Institute |
Compositions and methods of modulating anti-tumor immunity
|
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
CN110177553A
(zh)
*
|
2016-11-17 |
2019-08-27 |
北卡罗来纳大学教堂山分校 |
烷基吡咯并嘧啶类似物及其制备和使用方法
|
|
MA45887B1
(fr)
|
2016-11-28 |
2021-04-30 |
Teijin Pharma Ltd |
Cristal de dérivé de pyrido [3, 4-d] pyrimidine ou son solvate
|
|
WO2018097297A1
(ja)
|
2016-11-28 |
2018-05-31 |
帝人ファーマ株式会社 |
ピリド［３，４－ｄ］ピリミジン誘導体及びその薬学的に許容される塩
|
|
CA3045465A1
(en)
|
2016-12-05 |
2018-06-14 |
G1 Therapeutics, Inc. |
Preservation of immune response during chemotherapy regimens
|
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
|
JP2020506904A
(ja)
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
|
SG11201908531WA
(en)
|
2017-03-16 |
2019-10-30 |
Eisai R&D Man Co Ltd |
Combination therapies for the treatment of breast cancer
|
|
US10988466B2
(en)
|
2017-03-23 |
2021-04-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic derivatives useful as SHP2 inhibitors
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
MX393855B
(es)
|
2017-05-02 |
2025-03-21 |
Novartis Ag |
Terapia de combinación que comprende un inhibidor de raf y trametinib
|
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
|
TW201906818A
(zh)
*
|
2017-05-31 |
2019-02-16 |
美商５１１製藥公司 |
新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
|
|
WO2018218633A1
(en)
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
KR102659211B1
(ko)
|
2017-06-29 |
2024-04-18 |
쥐원 쎄라퓨틱스, 인크. |
G1t38의 형체 형태 및 그의 제조 방법
|
|
MX2020001253A
(es)
|
2017-08-03 |
2020-07-13 |
Novartis Ag |
Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
|
|
CA3073936A1
(en)
|
2017-08-25 |
2019-02-28 |
Sicor - Societa Italiana Corticosteroidi S.R.L. |
Ribociclib salts and solid state forms thereof
|
|
ES3049655T3
(en)
|
2017-08-31 |
2025-12-17 |
Novartis Ag |
Methods of selecting a treatment for breast cancer patients
|
|
US11286259B2
(en)
|
2017-09-29 |
2022-03-29 |
Hangzhou Solipharma Co., Ltd. |
Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
|
|
US11440912B2
(en)
|
2017-10-27 |
2022-09-13 |
Fresenius Kabi Oncology Ltd |
Process for the preparation of ribociclib and its salts
|
|
EP3709997A1
(en)
|
2017-11-16 |
2020-09-23 |
Novartis AG |
Pharmaceutical combination comprising lsz102 and ribociclib
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
WO2019123364A1
(en)
|
2017-12-22 |
2019-06-27 |
Shilpa Medicare Limited |
Novel polymorphs of ribociclib mono succinate
|
|
BR112020012635A2
(pt)
|
2017-12-22 |
2020-12-01 |
Ravenna Pharmaceuticals, Inc. |
derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase
|
|
WO2019133864A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Accutar Biotechnology |
DUAL INHIBITORS OF PARP1 and CDK
|
|
JP2021509680A
(ja)
|
2018-01-08 |
2021-04-01 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｇ１ｔ３８の優れた投与レジメン
|
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US11352341B2
(en)
*
|
2018-01-29 |
2022-06-07 |
Beta Pharma, Inc. |
2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
|
|
BR112020015431A2
(pt)
|
2018-02-15 |
2020-12-08 |
Nuvation Bio Inc. |
Compostos heterocíclicos como inibidores de quinase
|
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
CA3043066A1
(en)
|
2018-05-14 |
2019-11-14 |
Apotex Inc. |
Processes for the preparation of ribociclib and intermediates thereof
|
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
JP7359783B2
(ja)
|
2018-06-05 |
2023-10-11 |
クリネティックス ファーマシューティカルズ，インク． |
メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3107750A1
(en)
|
2018-07-27 |
2020-01-30 |
California Institute Of Technology |
Cdk inhibitors and uses thereof
|
|
CN113226318A
(zh)
|
2018-08-13 |
2021-08-06 |
北京智康博药肿瘤医学研究有限公司 |
用于癌症疗法的生物标记物
|
|
KR20210049847A
(ko)
|
2018-08-24 |
2021-05-06 |
쥐원 쎄라퓨틱스, 인크. |
1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
|
|
CA3112496A1
(en)
*
|
2018-09-13 |
2020-03-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
|
LT3873903T
(lt)
|
2018-10-31 |
2024-05-10 |
Gilead Sciences, Inc. |
Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
|
AU2019413360B2
(en)
*
|
2018-12-28 |
2025-05-22 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
WO2020140052A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
AU2020211071A1
(en)
|
2019-01-23 |
2021-07-15 |
Novartis Ag |
New crystalline forms of a succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
|
|
JP7493521B2
(ja)
|
2019-02-12 |
2024-05-31 |
ノバルティス アーゲー |
Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TWI875756B
(zh)
|
2019-05-05 |
2025-03-11 |
美商基尼特奇公司 |
Ｃｄｋ抑制劑
|
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
|
AU2020276695B2
(en)
|
2019-05-13 |
2025-12-18 |
Novartis Ag |
New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
|
|
TW202100184A
(zh)
|
2019-05-20 |
2021-01-01 |
瑞士商諾華公司 |
Mcl-1抑制劑抗體－藥物結合物及使用方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
EP3980411B1
(en)
*
|
2019-06-04 |
2025-07-23 |
Step Pharma S.A.S. |
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
US12479825B2
(en)
|
2019-11-07 |
2025-11-25 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
|
|
KR20220113986A
(ko)
|
2019-12-16 |
2022-08-17 |
루넬라 바이오테크 인코포레이티드 |
선택적 cdk 4/6 억제제 암 치료제
|
|
EP4077331A4
(en)
*
|
2019-12-16 |
2023-12-27 |
Lunella Biotech, Inc. |
SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS
|
|
WO2021126693A1
(en)
|
2019-12-18 |
2021-06-24 |
Crinetics Pharmaceuticals, Inc. |
Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
BR112022011998A2
(pt)
|
2019-12-20 |
2022-08-30 |
Novartis Ag |
Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
|
|
JP2023508357A
(ja)
|
2019-12-23 |
2023-03-02 |
アキュター バイオテクノロジー インコーポレイテッド |
エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
|
|
EP4081525B1
(en)
|
2019-12-23 |
2025-05-21 |
Crinetics Pharmaceuticals, Inc. |
Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
CN114245753A
(zh)
*
|
2020-03-27 |
2022-03-25 |
江苏康宁杰瑞生物制药有限公司 |
用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
|
|
JP2023525100A
(ja)
|
2020-05-12 |
2023-06-14 |
ノバルティス アーゲー |
Ｃｒａｆ阻害剤を含む治療的組み合わせ
|
|
JP7451765B2
(ja)
*
|
2020-05-12 |
2024-03-18 |
蘇州阿尓脈生物科技有限公司 |
Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
|
|
JP7406008B2
(ja)
*
|
2020-05-12 |
2023-12-26 |
蘇州阿尓脈生物科技有限公司 |
Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
|
|
EP4652997A2
(en)
|
2020-05-19 |
2025-11-26 |
Pharmacosmos Holding A/s |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
BR112022024484A2
(pt)
*
|
2020-06-11 |
2022-12-27 |
Lunella Biotech Inc |
Terapias contra o câncer com o inibidor seletivo de cdk4/6
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
|
KR20230138444A
(ko)
|
2020-11-24 |
2023-10-05 |
노파르티스 아게 |
Mcl-1 억제제 항체-약물 접합체 및 사용 방법
|
|
WO2022112942A2
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
IL304891A
(en)
|
2021-02-02 |
2023-10-01 |
Servier Lab |
Selective Protech BCL-XL compounds and methods of use
|
|
EP4308553A4
(en)
|
2021-03-19 |
2025-01-22 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
|
|
WO2022207788A2
(en)
|
2021-04-01 |
2022-10-06 |
Krka, D.D., Novo Mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4333847A1
(en)
|
2021-05-05 |
2024-03-13 |
Novartis AG |
Compounds and compositions for the treatment of mpnst
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
AU2022311961A1
(en)
|
2021-07-16 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
|
|
US12350276B2
(en)
|
2021-07-26 |
2025-07-08 |
Celcuity Inc. |
Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
|
|
KR20240041340A
(ko)
*
|
2021-07-27 |
2024-03-29 |
보로노이 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
|
TWI848533B
(zh)
|
2022-01-25 |
2024-07-11 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
US20240150322A1
(en)
*
|
2022-04-08 |
2024-05-09 |
Biolexis Therapeutics, Inc. |
CDK9 Inhibitors
|
|
CA3247581A1
(en)
|
2022-04-08 |
2023-10-12 |
Baerenkraft Therapeutics, Llc |
CDK9 INHIBITORS
|
|
CA3256012A1
(en)
|
2022-05-20 |
2023-11-23 |
Les Laboratoires Servier |
ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
|
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
TW202539669A
(zh)
|
2022-08-31 |
2025-10-16 |
美商亞文納營運公司 |
雌激素受體降解劑之給藥方案
|
|
EP4605088A1
(en)
*
|
2022-10-21 |
2025-08-27 |
Novartis AG |
Molecular glue degrader compounds and uses thereof
|
|
CN120187416A
(zh)
|
2022-11-11 |
2025-06-20 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
EP4626890A1
(en)
|
2022-12-01 |
2025-10-08 |
KRKA, d.d., Novo mesto |
Ribociclib salts and formulations thereof
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024231275A1
(en)
|
2023-05-05 |
2024-11-14 |
Astrazeneca Ab |
Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
US20250114357A1
(en)
*
|
2023-10-10 |
2025-04-10 |
Biolexis Therapeutics, Inc. |
Bifunctional protac and molecular glue compounds and methods of use thereof
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202540185A
(zh)
|
2023-11-22 |
2025-10-16 |
法商施維雅藥廠 |
抗cd74抗體藥物結合物及其使用方法
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
WO2025219830A1
(en)
|
2024-04-15 |
2025-10-23 |
Novartis Ag |
Pharmaceutical compositions of ribociclib
|
|
WO2025235331A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN120441576B
(zh)
*
|
2025-07-08 |
2025-09-26 |
山东大学 |
一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
|
|
CN120483984B
(zh)
*
|
2025-07-09 |
2025-10-10 |
山东大学 |
一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用
|